

## ABSTRACT

**Introduction:** Hypophysitis is an inflammatory disease of the pituitary that may mimic tumors. Primary hypophysitis has been classified as lymphocytic (LH), granulomatous (GH), and *xanthomatous* (XH). It has been recently proposed to be an IgG4-related autoimmune disease (serum IgG4 concentration: 135mg/dl), proven by tissue IgG4 immunostaining.

**Case description:** A 23-year-old man suffered from typical cluster type headache. Two years after the first symptoms, diabetes insipidus occurred. His testosterone level was low with low serum FSH and LH suggesting central hypogonadism, but all the other anterior pituitary hormone levels were normal. Sella MRI scan depicted a 17 mm inhomogenous mass. After the transsphenoidal surgery the pituitary tissue showed accumulation of foamy cells and *xanthomatous epithelioid cells*. After stopping the preoperative hydrocortisone therapy the headache returned. The endocrine work-up revealed hypoadrenia (morning cortisol: 96 nmol/l, ACTH: 3.38 pmol/l), hypothyroidism (ft4: 10.5 pmol/l), hypogonadism (testosterone: 3.44 nmol/l) with FSH: 3.3 mIU/l and LH: 2.8 mIU/l. Hydrocortisone, levothyroxine and testosterone were stepwise reintroduced. During the follow-up we could stop hydrocortisone, levothyroxine, whereas he has permanently required desmopressin and testosterone substitution. Occasionally headache attacks occur and disappear with glucocorticoid administration. Two years after the initial diagnosis the **hypophysitis was proven to be IgG4-related** by his tissue *IgG4 immunostaining* as well as by his elevated serum *IgG4 concentration* (815 mg/l).

**Conclusion:** We describe a case of *IgG4 related xanthomatous hypophysitis* causing cluster type headache permanently requiring ddAVP (desmopressin) and testosterone supplementation without need for maintenance medication with hydrocortisone and levothyroxin. In periods of headaches the patient requires glucocorticoids supporting the possible autoimmune origin of the disease.

We report a **23-year-old** man with XH who presented with cluster type headache, diabetes insipidus and pituitary MRI-proven intrasellar mass.

Since 2009 our patient suffered from recurrent **headache**. CT scan, ophthalmological, neurological investigations revealed no obvious cause of the symptoms

In April 2011 polyuria-polydipsia occurred, the endocrine investigations revealed **diabetes insipidus**. The anterior pituitary hormone levels: TSH: 1.3 mIU/l, FSH: 2.4 IU/l, LH: 3.7 IU/l,

PRL: 197 mIU/l, ACTH: 7.78 pmol/l, cortisol 08 h: 444 nmol/l despite low testosterone level (7.36 nmol/l). After initialization of ddAVP treatment, diuresis returned to normal.

The **pituitary MRI** scan revealed a 14x10x17 mm inhomogenous lesion with the disappearance of the hyperintense signal of the neurohypophysis.

In July 2011 **transsphenoidal surgery** was performed. The histology proved **xanthomatous hypophysitis**.

Without having any perioperative complication we could stop the glucocorticoid (GC) treatment. The headache resolved but the diabetes insipidus persisted.

**After the surgery** the anterior pituitary function was normal: serum cortisol 08 h: 404-445 nmol/l, ACTH: 6.49 pmol/l, FSH: 3.1 mIU/l, LH: 4.2 mIU/l, TSH: 1.61 mIU/l.

**2 months later** severe cluster type headache occurred. The endocrine investigations revealed **hypoadrenia, hypothyroidism** and peripheral **hypogonadism**:

serum cortisol 08 h.: 96 nmol/l, TSH: 1.32 mIU/l, ft4: 10.5 pmol/l, testosterone: 3.44 nmol/l, FSH: 3.3 mIU/l, LH: 2.8 mIU/l, ACTH: 3.38 pmol/l.

LHRH test results: FSH: 0.min.: 2.8, 30 min.: 4.7, 60 min.: 5.1 mIU/l, LH: 0.min.: 2.9, 30 min.: 13.5, 60 min.: 13.8 mIU/l.

The **postoperative pituitary MRI** scan proved the persistent presence of the inhomogenous mass.

After initialization of glucocorticoid replacement the headache disappeared. With levothyroxin, testosterone supplementation and gradually lowered dosage of GC and all symptoms disappeared but the diabetes insipidus. Despite of low IGF 1 (92 ng/ml, age matched reference rate: 117-329 ng/ml) and hGH (0.08 ng/ml) levels GH therapy was not

introduced. **Autoimmune screen** - ANA, antiCL, antiβ2GP, anti transglutaminase, anti TPO, anti parietal cell antibody - was negative.

**Regularly performed sella MRI scans** showed no change in tumor size and appearance after the surgery and after the introduction of hormone replacement therapy.

The patient requires GC supplementation only in case of recurrent cluster type headache, but no persistent replacement is needed.

In January 2013 we had the possibility to measure the patient's serum IgG4 level, which was markedly increased (**serum IgG4 concentration: 815 mg/l**) suggesting

the **xanthomatous hypophysitis to be IgG4-related**

## Conclusion:


In our case typical cluster type headache, diabetes insipidus and severe, persistent hypogonadism were the main symptoms of the xanthomatous hypophysitis (XH)

*The patient requires GC supplementation only in case of cluster type headache, but permanent testosterone replacement*


The patient's elevated serum IgG4 concentration is suggesting the XH to be IgG4 related disease

**The cause of the XH is still unknown, but as our data suggests it could be IgG4 related disease**


## Sella MRI




## Histology



## Immunohistochemistry




	Preoperative	Postoperative 1.	Postoperative 2. (headache)	Postop. 3. (1year)	Postop. 4. (2year)
TSH (mIU/L)	1.3	1.61	1.32	1.4	2.15
ft4 (pM/L)	14.7	14.7	10.5	14.9	14.9
ACTH (pg/mL)	7.78	6.49	3.38	6.36	3.41
Cortisol (nM/L)	444	445	96	445	562
FSH (IU/L)	2.4	3.1	3.3	1.4	2.1
LH (IU/L)	3.7	4.2	2.8	1.2	1.6
PRL (mIU/L)	197	88	202	151	129
Testosterone (nM/L)	7.36	3.87	3.44	2.05	12.24 (onT)
SHBG (um/L)	19.4	16.5	15.7	13.1	10.1
hGH (ng/mL)	0.13	0.07	0.05	0.15	4.2
IGF1 (ng/mL)	<25	<25	163	137	75.5



**IgG4 immunostaining, 20x**

**Patient's serum IgG4= 815 mg/l (0,815 g/l)**



## References

- Hattori Yet al: **A case of IgG4-related hypophysitis without pituitary insufficiency** J Clin Endocrinol Metab.2013 May;98(5):1808-11.
- Paola Leparati et al: **IgG4-Related Hypophysitis: A New Addition to the Hypophysitis Spectrum**, J Clin Endocrinol Metab, July 2011, 96(7):1971-1980
- P. Caturegli, C. Newschaffer, A. Olivi et al.: Autoimmune hypophysitis. Endocr Rev, 26 (2005), pp. 599-614
- R.D. Folkerth, D.L. Price Jr, M. Schwartz et al.: Xanthomatous hypophysitis, Am J Surg Pathol, 22 (1998), pp. 736-741
- M.G. Burt, A.L. Morey, J.J. Turner et al.: Xanthomatous pituitary lesions: a report of two cases and review of the literature, Pituitary, 6 (2003), pp. 161-168
- A. Gutenberg, V. Hans, M.J. Puchner et al.: Primary hypophysitis: clinical-pathological correlations, Eur J Endocrinol, 155 (2006), pp. 101-107
- S.S. Deodhare, J.M. Bilbao, K. Kovacs et al.: Xanthomatous hypophysitis: a novel entity of obscure etiology, Endocr Pathol, 10 (1999), pp. 237-241
- L.Aste et al: Xanthomatous hypophysitis mimicking a pituitary adenoma: case report and review of the literature, J. of Oncology Vol.2010, Art ID:195323, DOI:10.1155/2010/195323
- Seok Jin Jang: Xanthomatous hypophysitis: a case report and literature review, J.Korean Soc. Radiol 2011, 64:297-301
- Gutenberg A: Primary hypophysitis: clinical-pathological correlations, Eur J Endocrinol, 2006 jul, 155(1), 101-7

**Contact:** Eva Csajbók, MD; 1st Dept. of Internal Medicine, University of Szeged, Hungary.

**Correspondence:** email: ecsajbok@freemail.hu